Gen Digital GEN

Technology · Software - Infrastructure · Synthos Deep Dive · 2026-07-03

$31.02

Buy — Tactical

—

The Overview

Gen Digital sells the Norton, Avast, and LifeLock apps that protect your computer, phone, and identity from hackers, viruses, and identity theft — roughly 500 million people use its products. It's a subscription business, so money comes in steadily every month, and it's very profitable: it keeps about 76 cents of every sales dollar before overhead.

Here's the honest picture. The stock is cheap — you're paying about 9 dollars for every dollar the company earns each year (a bargain by tech standards), and it throws off a lot of spare cash. But the company isn't really growing much on its own; last year's big "27% growth" number came mostly from buying another company (MoneyLion, a financial-app maker), not from selling more of its core product. And Gen owes a lot of borrowed money — about $8 billion — which is the main thing that could hurt shareholders if business softens.

Our verdict is Watch — meaning it's interesting and fairly priced, but there's no urgent reason to rush in, and no outside experts we track have made a case for it.

Here's what the three scores mean in everyday terms:

Downside Risk 6/10 (a bit above average). The cheap price and steady cash are protective, but the heavy debt load means a bad year would hurt more than for a debt-free company.
Growth Quality 5/10 (middle of the road). Steady and profitable, but growing slowly — the earnings gains come mostly from paying down debt and buying back stock, not from selling much more.
Exponential Potential 3/10 (low). This is a mature, slow-and-steady business. Don't expect it to double quickly; its one wild card is the new push into financial-wellness apps.

The one big worry: the debt. If subscriber growth stalls or the economy squeezes consumers, that ~$8 billion of borrowings becomes a heavier weight.

Putting a number on it: our fair-value estimate is $30 against a current price of $31.02 — a premium price for a business we still like.

Target entry zone $27 – $31 accumulate in this band; ideal adds on a dip toward the 50-day average near $27

Our summary metrics

Downside Risk (lower = safer)6/10High

Cheap (9× fwd non-GAAP) & huge FCF, but net-debt/EBITDA ~3.4× and beta 1.2 — leverage is the whole risk.

Growth Quality5/10Moderate

FY26 +27% was M&A-inflated; organic is low-single-digit; 15% non-GAAP EPS growth is debt-paydown + buyback, not demand.

Exponential Potential3/10Low

Mature consumer-security cash cow; MoneyLion/financial-wellness pivot is the only real optionality, unproven.

Fair value$30 $23–$40

What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

Exponential Potential

Exponential Potential3/10Low

Mature consumer-security cash cow; MoneyLion/financial-wellness pivot is the only real optionality, unproven.

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 12%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $31, earnings would have to compound roughly 12% a year for 10 years (9% discount rate). Analysts forecast ~11%/yr, so the market is pricing in about what the Street expects.

Reference table

Street consensus	$27 (high $27 / low $27; 11 Buy · 9 Hold · 1 Sell) — thin PT coverage; context, not our anchor
Valuation	16.7× trailing GAAP EPS · ~10.4× TTM non-GAAP · ~9.2× FY27E non-GAAP · EV/S 4.8× · EV/EBITDA 10.3×
Technicals	Mixed — $26.67, −17% off 52-wk high, above 50/200-DMA, RSI 69 (near overbought), −10.5% 12-mo (SPY +21%)
Conviction	Low — 0 expert voices in the KB; quant/fundamentals only
Position sizing	Small / satellite value-income, ≤2% if owned — not a core holding

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for GEN — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 71.

MACD 12 / 26 / 9 · trend & momentum

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago

Solid = GEN · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$31.02

Market cap$19B

P/E trailing18×

P/E FY26E / FY27E12× / 11×

EV / Sales5.2×

EV / EBITDA11.4×

Gross margin78.0%

Net margin20.7%

Dividend yield1.61%

Beta1.201

52-wk range$18 – $31

RSI(14)61

50 / 200-DMA$27 / $25

12-mo return+1% (SPY +19%)

Street target$28 ($27–$30)

Analyst grades10 Buy · 10 Hold · 1 Sell

FMP ratingB+

Next earnings2026-08-06 (Q1'27 earnings; Street EPS est $0.69, rev ~$1.31B)

1. What it is

Gen Digital Inc. (NASDAQ: GEN) — formerly NortonLifeLock, and before that Symantec's consumer arm — is a global consumer cyber-safety and digital-wellness company headquartered in Tempe, Arizona. Its brands include Norton, Avast, AVG, Avira, LifeLock, and (newly) MoneyLion. The flagship is Norton 360, a subscription bundle covering antivirus, VPN, dark-web monitoring, and identity-theft protection for ~500M users across 150+ countries. Fiscal year ends in early April (FY26 ended 2026-04-03).

Revenue mix (FY2026, from filings):

By segment: Core Consumer Security $3.34B (67%) · Endpoint Security & Management $1.66B (33%). (Note: FMP's segment labels shift year to year — FY25 was reported as "Cyber Safety Revenues"; the newer split reflects the post-MoneyLion, "cyber safety + financial wellness" platform framing.)
By geography: Americas $3.53B (71%) · EMEA $1.06B (21%) · Asia-Pacific $0.41B (8%). Heavily Americas-weighted, which concentrates both pricing power and US-consumer-cyclicality risk.

The strategic story management is now telling is a pivot from pure cyber-safety to a combined "cyber safety + financial wellness" platform — the rationale for the MoneyLion acquisition (closed FY26, ~$1.0B of the year's acquisition spend) — plus positioning Gen as "the trust layer" for the coming agentic-AI era. That thesis is unproven; the base business remains mature consumer security.

2. The expert thesis — why the panel is bullish (traceable)

There is no expert coverage of Gen Digital in the Synthos knowledge base. total_claims = 0; zero net-bullish voices; zero cautionary voices. No claim_id exists to cite, and this note fabricates none.

That absence is itself information: GEN is a mid-cap, mature software-value name, not a story stock that the high-signal investor/podcast panel Synthos distills tends to debate. The verdict here is therefore fundamentals- and quant-driven only — built from the FMP financials, analyst estimates, management's own guidance (§9, half-weighted), and the Synthos scoring framework. Readers should weight it accordingly: there is no independent conviction layer confirming or contradicting the numbers.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	6 · Above-average	Cheapness (~9× fwd non-GAAP, ~9.5% FCF yield) and subscription stickiness cushion the downside, but net-debt/EBITDA ~3.4×, beta 1.2, a negative-working-capital / <1 current ratio, and 84% of assets in goodwill/intangibles all raise the floor of risk. Leverage is the whole story.
Growth Quality	5 · Middling	76% gross margin and ~46% EBITDA margin are excellent, and ROE is optically high — but that ROE is flattered by a thin, goodwill-heavy equity base. FY26's +27% revenue was M&A-inflated; organic growth is low-single-digit and non-GAAP EPS growth (~15%) is driven more by debt paydown and buybacks than by demand.
Exponential Potential	3 · Low	A mature consumer-security cash cow past its growth phase. The MoneyLion / financial-wellness pivot is the only genuine optionality, and it is early and unproven. No acceleration in the core.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. All EPS figures below are non-GAAP (the basis management guides to and the Street models); GAAP EPS runs materially lower due to amortization and interest.

Case	Key assumptions	Fair value
Bull	MoneyLion cross-sell works, organic growth reaccelerates toward mid-single-digits, debt paydown lifts EPS; FY28E non-GAAP EPS ~$3.35 earns a re-rating to ~12× as leverage falls.	~$40 (+50%)
Base (our anchor)	Guidance roughly hits — FY27E non-GAAP EPS ~$2.90 (mgmt guide $2.85–2.95), grinding to ~$3.20 FY28E; a levered low-growth compounder holds a ~10× multiple.	~$30 (+12%)
Bear	Consumer softness / churn stalls organic growth, MoneyLion integration disappoints, and the leverage caps the multiple; FY27E EPS at the low end (~$2.85) on a de-rated ~8×.	~$23 (−14%)

Synthos fair value = the base case, ~$30 (+12%), with the full $23–$40 span as the honest range. Our base sits modestly above the Street's $27 consensus (we give some credit to continued buyback-driven EPS accretion and debt paydown), and our bear is below it (we take the leverage and organic-growth risk seriously). This is a tracked call — the Forecaster Scorecard grades it once it matures. Note the Street PT coverage here is unusually thin (single $27 target in the feed), so treat consensus as a weak anchor.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). GEN is neither a high-quality organic compounder nor an exponential — it is a levered, mature cash cow:

Forward growth: revenue CAGR FY26→FY29E ~7.4% ($5.0B → $6.19B on consensus), but a large slice of that is the annualization of MoneyLion, not organic demand. Non-GAAP EPS CAGR ~13% — respectable, but the engine is financial (buybacks + deleveraging), not top-line.
Acceleration (the 2nd derivative): the FY26 headline looks like acceleration (+27% reported) but is an M&A artifact. Underlying organic growth is flat-to-low-single-digit and not accelerating. Management guides FY27 revenue to $5.325–5.425B — only ~7–9% over FY26, again partly the MoneyLion anniversary.
Room to run: at $16B market cap the company is not size-constrained, but the consumer-security TAM is mature and competitive (free/bundled antivirus from Microsoft, Apple, Google is a structural headwind). The financial-wellness angle (MoneyLion) is the only new TAM, and it is unproven and competitive.
Reinvestment runway: capex is trivial (~0.4% of revenue), so this is an asset-light cash generator — but that cash goes to interest, dividends, and buybacks, not high-return organic reinvestment.

Exponential Potential: Low (3/10). Own GEN, if at all, for its ~9.5% FCF yield and cheap multiple — an income/value idea — not for growth or a multibagger. The honest framing is a mature software cash cow carrying a lot of debt.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY26 $5.00B, +27% (FY25 $3.94B, FY24 $3.80B). Caveat: the FY26 jump is heavily inflated by the MoneyLion acquisition (~$1.0B of acquisition spend in the cash-flow statement) and by segment reclassification — organic growth is low-single-digit. Management's own release even headlines "growth accelerating to double-digits," but that is the reported (M&A-aided) figure, not organic.
Quarterly trajectory: Q1'26 $1.257B → Q2 $1.220B → Q3 $1.240B → Q4'26 $1.283B (+27% YoY as MoneyLion consolidated). Sequential trend is flattish, consistent with a mature core plus a step-up from the acquisition.
Margins: gross 76.3% TTM, EBITDA 46.3% TTM, non-GAAP operating margin ~50%. Excellent and stable — the hallmark of a subscription cash cow.
Earnings: GAAP net income $973M FY26 (GAAP diluted EPS $1.57, +53% — but flattered by a large non-operating item this year); non-GAAP diluted EPS $2.56, +15%. Use the non-GAAP figure for valuation, but know GAAP is much lower.
Cash flow: operating CF $1.55B, capex only −$22M, FCF $1.52B FY26 — a ~9.5% FCF yield on market cap. This is the real attraction: cash generation is fat and consistent.
Balance sheet (the risk): total debt ~$8.26B, cash $402M, net debt ~$7.86B; net-debt/EBITDA ~3.4× (TTM basis). Current ratio 0.40 (working capital negative −$1.63B). Equity is thin ($2.6B) and ~84% of total assets are goodwill + intangibles — a legacy of the LifeLock/Avast/MoneyLion deal stack. Debt is serviceable against $1.5B FCF, but it is the dominant risk.

6. Valuation — priced in or room?

On the surface GEN is cheap: ~10.4× TTM non-GAAP EPS, ~9.2× FY27E non-GAAP (management guide $2.85–2.95), EV/EBITDA 10.3×, EV/S 4.8×, and a ~9.5% FCF yield. For a 76%-gross-margin subscription business, those are value-stock multiples. The GAAP P/E of 16.7× looks higher because GAAP EPS is depressed by amortization and interest — non-GAAP is the fair lens.

The reason it's cheap is not a mystery: low organic growth + high leverage. The market is pricing GEN as a levered, ex-growth cash cow, not a grower — and that's roughly correct. The bull case is that the multiple re-rates modestly (toward ~12×) as debt falls and MoneyLion adds a growth vector; the bear is that consumer-security commoditization and the debt keep the multiple pinned at ~8×. Street targets (context): consensus, high, and low all sit at $27 in the feed — essentially "fairly valued, flat from here," and notably thin coverage. Our ~$30 base is modestly more constructive on continued EPS accretion. This is a cheap-but-for-a-reason situation, not a hidden gem.

7. Technicals (from the tech block)

Trend: modestly up. $26.67 sits above the 50-DMA ($23.38) and 200-DMA ($24.44), MACD +0.42 (positive) — a near-term recovery posture.
Location: −17.1% off the 52-week high ($32.16) and +49% off the 52-week low ($17.89) — well off the lows but still meaningfully below the highs; max drawdown from peak −17%.
Momentum: RSI(14) 69 — right at the overbought threshold (70). After a +42.5% 3-month run, the near-term entry looks stretched; this is not a low-risk chase point.
Relative strength (the tell): GEN −10.5% 12-mo vs SPY +20.6% and QQQ +30.3% — a laggard over the year despite the recent bounce. The 3-month (+42.5% vs SPY +13.7%) reflects a sharp mean-reversion off the lows, not established leadership.
Read: technicals are mixed. The recovery is real but momentum is stretched (RSI 69) and the 12-month picture is underperformance. A better-risk entry would be a pullback toward the rising 50-DMA (~$23–24) rather than into overbought.

8. Moat & competitive position

Gen's moat is a brand + distribution + switching-inertia moat, not a technology moat. Norton/Avast/LifeLock are trusted household names with an enormous installed base (~500M users), sold through retail, OEM, telco, and DTC channels; auto-renewing subscriptions and identity-monitoring lock-in create sticky, high-margin recurring revenue. That is a real but defensive moat. The structural threat is that basic antivirus is increasingly free and bundled by Microsoft (Defender), Apple, and Google, pushing Gen to differentiate on identity protection, VPN, and now financial wellness. The MoneyLion pivot is an attempt to widen the moat into adjacent consumer-fintech; it is early.

Peer set (market cap): the FMP peer list is a loose "infrastructure software / security" basket rather than pure comps — Akamai $16.5B, Check Point $14.2B, Corpay $23.0B, Dynatrace $13.0B, F5 $23.0B, GoDaddy $11.7B, Kaspi $17.1B, Okta $23.5B, Rubrik $17.2B, Unity $12.8B. The closest true comparables are Check Point (a slower-growth, cash-generative security name) and McAfee/Avast-style consumer security (mostly private). GEN screens as one of the cheaper, higher-FCF-yield, but also more-levered and slower-growth names in the group.

9. Management, capital allocation & guidance

Capital allocation: classic levered cash-cow playbook — FY26 returned ~$634M via buybacks and ~$312M in dividends (dividend recently set at $0.125/quarter), repaid ~$145M of net debt, and spent ~$1.0B on the MoneyLion acquisition. The bet is that acquisitions + buybacks + gradual deleveraging compound EPS faster than the slow-growing core. Reasonable, but it depends on integration and on rates staying manageable against the debt.
Insider activity (mixed signal): the most notable recent trades are a director purchase — John Chrystal bought 3,000 shares at $27.06 on 2026-06-04 (a modest but genuine open-market buy) — against a director sale — Ondrej Vlcek (the former Avast CEO) sold 100,000 shares at $24.78 on 2026-06-10. The CEO (Pilette), CFO (Derse), and COO (Ko) received large equity awards in May 2026 (compensation, not open-market buys). Net: no alarming cluster of discretionary selling, and one small insider buy is a mild positive.
Management's own guidance (half-weighted — their book): the SEC 8-K earnings release (filed 2026-05-07, FY26 Q4) is a real earnings release and states management's forward guidance: Q1 FY27 revenue $1,300–1,325M and non-GAAP EPS $0.68–0.70; full-year FY27 revenue $5,325–5,425M and non-GAAP EPS $2.85–2.95. Management framed FY26 as "our strongest results in a decade… revenue crossing $5 billion" and raised FY27 guidance for both revenue and EPS. Half-weight this: it's management talking its own book, and the headline "double-digit growth" leans on the M&A-aided reported figure, not organic demand. The direction (steady growth + rising EPS) is credible; the framing is promotional.

10. Catalysts & what to watch

Next earnings: 2026-08-06 (Q1'27; Street EPS $0.69, revenue ~$1.31B — right in management's guide). The key line: organic (ex-MoneyLion) revenue growth and churn/retention — is the core actually growing, or just the acquisition?
MoneyLion integration & cross-sell: evidence that financial-wellness attach is working (or not) — the swing factor for the bull case.
Deleveraging pace: net-debt/EBITDA trending down toward ~3× or below would support a re-rating; stalling would confirm the bear.
Consumer health: GEN's DTC subscriptions are consumer-discretionary-adjacent; a consumer slowdown pressures adds and renewals.
Competitive: any acceleration in free/bundled security from Microsoft/Apple/Google eroding the paid-antivirus base.

Thesis tripwires (what would change the call): organic revenue turning negative for two quarters; net-debt/EBITDA rising rather than falling; a MoneyLion write-down or integration miss; or FCF dropping below ~$1.3B.

11. Key risks

Leverage (structural, the dominant risk): ~$8.3B gross debt, net-debt/EBITDA ~3.4×, current ratio 0.40, thin goodwill-heavy equity. Serviceable against $1.5B FCF today, but it magnifies any operational stumble and limits strategic flexibility if rates or results move against the company.
Low organic growth / commoditization: the core consumer-security market is mature, and free/bundled antivirus from platform owners is a persistent structural headwind. The reported growth rate overstates the underlying trend.
M&A-dependent story: EPS growth leans on acquisitions and buybacks; MoneyLion integration and fintech execution are unproven, and consumer-fintech is competitive and regulated.
Goodwill/intangible risk: ~84% of assets are goodwill + intangibles from the deal stack — impairment risk if any franchise underperforms.
No expert corroboration: with zero KB coverage, there is no independent conviction layer; the call rests entirely on the quant/fundamental read.

12. Verdict, position sizing & monitoring

Watch. Gen Digital is a genuinely cheap (~9× forward non-GAAP), high-FCF-yield (~9.5%), 76%-gross-margin subscription cash cow — a legitimate value/income idea. But it is not a growth story: FY26's +27% was M&A-inflated, organic growth is low-single-digit, and a ~$8.3B debt load (net-debt/EBITDA ~3.4×) is the entire risk. There is no expert coverage in the Synthos KB, so this verdict is quant/fundamentals-only and should be weighted accordingly. The stock is fairly valued near our $30 base with a ~$23–$40 range; the recent +42% three-month run into an RSI of 69 argues against chasing here.

Sizing: if owned at all, small / satellite (≤2%) as a value-income position — not a core holding. Prefer entry on a pullback toward the 50-DMA (~$23–24) rather than into overbought strength.
Monitoring: re-underwrite on the tripwires in §10 (organic growth, deleveraging, MoneyLion, FCF); formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $26.67.
Single biggest risk: the ~$8.3B debt load against a slow-growing, mature core — leverage turns a modest operational miss into a real equity problem.

Provenance & disclosures

Traceability: 0 KB claims, breadth 0 — no expert coverage exists for GEN in the Synthos KB, so no claim_ids are cited and none are fabricated. The verdict is fundamentals- and quant-driven.
Data as-of: fundamentals FY26 / Q4 ended 2026-04-03 · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates; EPS figures in the valuation are non-GAAP (management/Street basis), which runs above GAAP EPS.
Management caveat: the FY26 Q4 8-K guidance (revenue $5.325–5.425B, non-GAAP EPS $2.85–2.95 for FY27) is management's own book, half-weighted by design; the "double-digit growth" framing leans on M&A-aided reported figures.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").